Chris joined Phoenix in 2017 and has over 15 years of private equity experience. He sits on the Investment Committee and focuses his investment activity on all things data, digital and technology.
Dr. Hudd has been central to many important technology developments over the last 30 years in the field of digital and inkjet printing, reflecting over 250 patents to his name and recognised for many commercial industry successes. His career to date has spanned over four decades in developing new disruptive technologies, including over thirty years in commercialising industrial inkjet technology. Dr.Hudd was a key inventor of the fundamental pioneering uv cure inkjet patents that today underpin a number of the current important industrial inkjet applications. In 1996, Dr. Hudd founded Xennia Technology as an inkjet consultancy firm that went on under his leadership to become the world leading industrial inkjet integrator with uniquely recognised capabilities from chemistry through software to engineering. Dr. Hudd sold Xennia to Royal TenCate in 2008. In 2014, Dr. Hudd founded Alchemie Technology with the goal of transforming the environmental footprint of the textile industry.
Previously, Ms. Kong was an independent advisor to private equity firms and large corporates. Ms. Kong was formerly the Managing Partner at Hewlett Packard Enterprise’s advisory and consulting services. Prior to that, Ms. Kong was an Associate Director at EY’s transaction advisory services and an Executive Advisor at KPMG’s deal advisory team. Ms. Kong is a trustee of the Rosetrees Trust, a charitable foundation that has supported cutting-edge medical research for over 30 years. She also serves on the Risk & Audit Committee of The Biochemical Society, a global community founded in 1911, representing the breadth of the molecular biosciences. Ms. Kong earned her B.Sc. in Business Information Technology and M.Com. in International Business from the University of New South Wales. She is also a qualified accountant (ACCA).
